市场调查报告书
商品编码
1417584
全球负压伤口治疗 (NPWT) 市场评估:按产品类型、伤口类型、最终用户、地区、机会、预测(2017-2031 年)Negative Pressure Wound Therapy Market Assessment, By Product Type, By Wound Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
预计2023年全球负压伤口治疗(NPWT)市场规模将达23.1亿美元,2031年将达34.9亿美元,2023-2031年预测期内复合年增长率为5.28%。负压伤口治疗(NPWT)市场是全球先进伤口护理管理市场中成长最快的部分。这个市场的驱动因素是糖尿病和相关足部溃疡盛行率的不断上升、NPWT的持续技术进步和创新、包括溃疡伤口、手术伤口和烧伤在内的伤口病例数量的增加,以及对负压伤口治疗的需求不断增加。随着需求的增加。糖尿病足溃疡是糖尿病患者的一大担忧,随着糖尿病的流行,糖尿病足溃疡患者的数量不断增加,进一步推动了NPWT的需求。负压伤口治疗已被证明在短时间内管理和治疗伤口方面非常有效,进一步推动了NPWT市场的需求。
此外,由于外科手术数量的增加和道路事故数量的增加,需要伤口治疗的患者数量也在增加,进一步推动了全球负压伤口治疗(NPWT)市场的成长。然而,由于缺乏实施 NPWT 所需的熟练专业人员和技术专长以及设备成本高昂,该市场受到限制。
例如,2023年8月,专门生产医用真空设备的瑞士公司Medela AG宣布推出名为 "Invia Integrated Dressing" 的新型一体化敷料产品,扩大其负压伤口护理产品组合。该敷料于 2023 年 7 月获得 FDA 批准,设计用于与 Medela 的 NPWT 帮浦、Liberty 和 Motion 搭配使用。这种一体式敷料是一种 "即贴即剥" 黏合剂,具有三层流体处理垫,包括亲肤硅胶黏合边框和快速连接器,易于操作。
糖尿病及其相关足部溃疡的盛行率不断上升,大大推动了负压伤口治疗(NPWT)市场的发展。糖尿病是一种与生活方式相关的疾病,伴随多种併发症,其中糖尿病的主要併发症之一是足部溃疡。糖尿病足溃疡 (DFU) 是长期且控制不佳的糖尿病的常见且高度发病的后果,估计约 19-34% 的糖尿病患者一生中都会受到影响。NPWT 是治疗糖尿病患者糖尿病足溃疡的有效且经济有效的方法。多项研究也支持负压伤口治疗可促进糖尿病足溃疡的伤口有效癒合。例如,根据 2023 年 9 月发表在《Nature》杂誌上的一项研究,PRDX2(过氧化还原蛋白 2)透过其抗氧化作用促进 NHDF 增殖和迁移。它也被提议作为负压伤口治疗的机制,用于治疗糖尿病足溃疡等慢性伤口。
负压伤口治疗不断发展的技术进步和创新将对市场产生积极影响。压力设定范围的最佳化、敷料黏附力的提高以及治疗中使用的敷料的湿度控制等技术创新可能会推动 NPWT 的使用和需求,进一步推动市场成长。技术进步使 NPWT 设备更有效、更易于使用且更实惠,从而在医院和家庭护理机构中得到越来越多的采用。市场进入者正在寻求利用创新解决方案来促进成长的机会。
例如,2023 年 4 月,3M 宣布其 Veraflo Cleanse Choice Complete 敷料和 Veraflo Cleanse Choice 敷料获得 FDA 批准,该敷料可透过流体机械方式去除伤口中的感染性物质、非活性组织和伤口碎片。这可以改善肉芽形成并加速伤口癒合过程。除了 3M 的 Veraflow 产品组合(包括负压伤口护理产品)之外,这些敷料也至关重要。
本报告研究分析了全球负压伤口治疗(NPWT)市场,提供市场规模和预测、市场动态、主要参与者趋势和前景等。
Global negative pressure wound therapy (NPWT) market size was valued at USD 2.31 billion in 2023, and is expected to reach USD 3.49 billion in 2031, with a CAGR of 5.28% for the forecast period between 2023 and 2031F. The negative pressure wound therapy (NPWT) market is a fast-growing segment within the global advanced wound care management market. The market is driven by several factors, including the increasing prevalence of diabetes and associated foot ulcers, growing technological advancements and innovations in NPWT, growing cases of wounds including ulcers wounds, surgical and burn wounds, and growing demand for negative pressure wound therapies. Diabetes foot ulcer is a major concern for diabetic patients and with the increasing prevalence of diabetes, the diabetic foot ulcers patients are increasing, further driving the demand for NPWT. Negative pressure wound therapies have proven highly effective in managing and curing wounds in less time, further driving demand in the NPWT market.
Additionally, a growing number of surgical procedures and increasing cases of road accidents are leading to an increasing number of patients requiring wound care, further fueling the market growth for the global negative pressure wound therapy (NPWT) market. However, the lack of skilled professionals and technical expertise required for providing NPWT and the high cost of equipment are some of the restraints for the market.
For instance, in August 2023, Medela AG, a Swiss company specializing in medical vacuum devices, announced the expansion of its negative pressure wound therapy portfolio with a new integrated dressing product named 'Invia Integrated Dressing'. The dressing received FDA approval in July 2023 and is designed to work well with Medela NPWT pumps, Liberty, and MotionTM. The integrated dressing is a 'peel-and-stick' adhesive, having a three-layer fluid handling pad that contains a skin-friendly silicone adhesive border with a quick-connector for easy handling.
The growing prevalence of diabetes and associated foot ulcers significantly drives the negative pressure wound therapy (NPWT) market. Diabetes, being a lifestyle disorder, comes with several comorbidities, one of the major complications in diabetes is foot ulcers. Diabetic foot ulcers (DFU) are a common, highly morbid consequence of longstanding and poorly managed diabetes and are estimated to affect about 19-34% of diabetes patients in their lifetime. NPWT is an effective and cost-efficient method for managing diabetic foot ulcers in diabetic patients. Several research supports the fact that negative pressure wound therapy promotes efficient wound healing in diabetic foot ulcers. For instance, according to research published in Nature, in September 2023, PRDX2 (Peroxiredoxin 2) promotes NHDF proliferation and migration through its antioxidant properties, which is the proposed mechanism of negative pressure wound therapies for the treatment of chronic wounds like diabetic foot ulcers.
Growing technological advancements and innovations in negative pressure wound therapy positively impact the market. Several innovations like optimization of range of pressure settings, improved adhesive nature of dressing, and humidity management of dressings used in therapies are likely to promote the use and demand of NPWT, further fueling the market growth. Technological advancements make NPWT devices more effective, user-friendly, and affordable, thereby driving their adoption in both hospitals and home healthcare settings. Market players are dedicated to harnessing the opportunity to enhance their growth in the market through innovative solutions.
For instance, in April 2023, 3M announced that it received FDA approval for Veraflo Cleanse Choice Complete Dressing and Veraflo Cleanse Choice Dressing for hydromechanical removal of infectious materials, non-viable tissues, and wound debris from wounds, thus reducing the number of surgical debridement required. It will improve the granulation formation and speed up the wound healing process. These dressings are crucial in addition to 3M's Veraflow portfolio containing negative pressure wound therapy products.
Conventional negative pressure wound therapies include reusable components thus minimizing the wastage and saving resources. The segment is expected to gain traction from healthcare professionals and hospitals as the vacuum devices can be reused and dressing needs to be changed, thus saving effort and resources for repeated purchase. It provides better management of exudates from severe wounds, improving the wound-healing process. Despite the popularity of conventional NPWT, single-use negative pressure wound therapy segment is expected to grow faster owing to post-pandemic alertness.
With high investment in research and development activities, technological advancements by key players, and highly advanced healthcare infrastructure in North American countries like the United States and Canada, the region is expected to dominate the market with the highest value share. The supportive government initiatives for managing blood-related diseases are driving the growth of the market in the region. The high prevalence of diabetes and associated diabetic foot ulcers and other types of pressure ulcers in the region is contributing to the dominance of North America in the global negative pressure wound therapy market.
Market players are expanding their product offerings and giving their customers access to a wide range of cutting-edge and novel products. To gain market share, companies are expanding the range of products they offer. Industry participants use a variety of growth methods, including collaborations, mergers and acquisitions, product launches, and the development of new goods, to bolster their positions in the market.
In May 2023, Smith & Nephew plc announced that its PICO single-use negative pressure wound therapy systems have received an Innovative Technology contract from Vizient, Inc. The contract was given to Smith & Nephew plc, based on the recommendation of hospital experts who serve on one of Vizient's member-led councils. Innovative Technology program aims to improve clinical care and enhance the business model for health care organizations with potential products recommended by healthcare professionals.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.